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INTRODUCTION
Alternative splicing is the process allowing several different mRNA molecules to be synthesised from a single gene. Deep sequencing approaches in the last decade have revealed that virtually all human genes produce at least two alternative mRNA isoforms Pan et al, 2008) . The key signals for splicing are the branch point and the 5' and 3' splice sites. These are all strictly required for splicing, and their core sequences are highly conserved. Consequently, alternative splicing control is seldom exerted through these sites themselves. Cis-acting splicing regulatory elements (splice enhancers or silencers) are instead found in introns or exons, and they regulate sites that can be tens or even hundreds of nucleotides apart. Their combined effects define a splice "code" that determines which mRNAs are produced when a pre-mRNA molecule is processed in any given cell type and at any differentiation stage Fu, 2004) .
Essentially, splicing regulatory elements act by binding RNA-binding proteins (RBPs).
However, pre-mRNAs are bound by multiple RBPs, and splicing outputs depend on the relationships between these RBPs. For example, QKI competes with PTBP1 to control the inclusion of the CAPZB exon 9 (Hall et al, 2013) , while HNRNPLL and HNRNPL act as antagonists to control the splicing of CHRNA1 mRNA (Rahman et al, 2013) . Conversely, RBFOX1 stimulates HNRNPM-mediated control of the splicing of many exons (Damianov et al, 2016) . Hence, looking at a splicing regulation exerted by a single RBP is insufficient for predicting splicing patterns, and there are not enough results from experiments in living cells done on a genome-wide scale to provide a global view of the functional interactions between RBP pairs (Dassi, 2017) .
Here, we address the functional relationships of two RBPs involved in alternative splicing control: CELF1 (CUGBP Elav-like family member 1, also called CUGBP1), and ELAVL1 (ELAVlike RNA-binding protein 1, also known as HuR). Both proteins interact with their RNA ligands through three specific domains nammed "RNA-recognition motifs". The first two domains share 31% identity between CELF1 and ELAVL1, and the third shares 46%. Both proteins control 3 45 50 55 60 alternative splicing (Kalsotra et al, 2008; Philips et al, 1998; Tang et al, 2015; Chang et al, 2014) , and they both oligomerise (Cosson et al, 2006; Fialcowitz-White et al, 2007) . They also coimmunoprecipitate, indicating that they bind to the same RNAs (Le Tonquèze et al, 2010) . Finally, the phenotypes caused in mice by disrupting their genes look much alike. In a pure genetic background, inactivating either Elavl1 or Celf1 causes embryo death (Cibois et al, 2012; Katsanou et al, 2009) . Conditional inactivation of Elavl1 (Chi et al, 2011) and constitutive inactivation of Celf1 in a mixed genetic background (Boulanger et al, 2015) showed that both ELAVL1 and CELF1 are required for spermatogenesis.
Despite their resemblances, ELAVL1 and CELF1 are highly divergent. The human reference isoform for CELF1 is significantly longer than the ELAVL1 one (489 versus 326 amino acids). This is due to a longer linker region between the second and the third RNA recognition motifs, a difference that probably results in new properties. Most importantly, the RNA binding specificities of these two proteins differ: CELF1 interacts with GU-rich elements, while ELAVL1 interacts with AU-rich ones. CELF1 binding to GU-rich elements most often leads to mRNA decay and represses or stimulates translation (Cibois et al, 2010; Chaudhury et al, 2016; Vlasova et al, 2008; Masuda et al, 2012) , whereas ELAVL1 binding to AU-rich elements generally stabilizes the bound mRNA (Mukherjee et al, 2011; García-Domínguez et al, 2011; Lafarga et al, 2009; Chen et al, 2002; Peng et al, 1998) . Their limited similarities make this pair of proteins attractive for the exploration of RBP relationships in alternative splicing control. Here, we show that CELF1 and ELAVL1 control together the splicing of their target genes, and that they directly interact in cell nuclei. Finally, we demonstrate the prognostic value for various cancers of looking at the combined mRNA levels of CELF1 and ELAVL1, indications that are unseen when the levels are considered separately. Our discoveries point to strong functional interactions between CELF1 and ELAVL1 that were not expected given their weak affinity and dissimilar molecular functions, thus underlining the clinical importance of simultaneously considering the molecular functions of RNA-4 70 75 80 85 90 binding proteins.
RESULTS AND DISCUSSION

CELF1 and ELAVL1 similarly control pre-mRNA splicing
We used RNA interference to deplete CELF1 and ELAVL1 either separately or simultaneously in HeLa cells. To reduce toxicity, we used siRNA quantities which left at least 25% of these proteins. The two proteins were knocked down equally with single and double siRNAs, and there was no apparent cross regulation between the proteins ( Figure S1A ). Having established our experimental conditions, we extracted RNAs from control and depleted cells to analyse RNA splicing by exon array hybridization. Exon arrays are used to infer splicing patterns, with results comparable to those from deep RNA sequencing Raghavachari et al, 2012) . For each of the 117,841 probes, we calculated a normalized exon probe value corresponding to the exon probe's fluorescence intensity normalized by the expression of the exon probe's gene. Based on these values, replicate conditions cluster together ( Figure S1B ). We filtered the exon probes of interest according to two criteria: they should target a gene that is reasonably expressed (among the 75% most-expressed genes under at least one condition); and based on CLIP-seq experiments carried out in HeLa cells, they should target an RNA ligand of both CELF1 and ELAVL1 (Table S1) (Le Tonquèze et al, 2016; Uren et al, 2011) . This resulted in 18,714 exon probes in 1,299 genes. Of these, 62 exon probes in 57 genes have a significantly different normalized value in at least one test (depletion) compared with the control condition (control siRNA-transfected cells), at a false discovery rate (FDR) of 0.1. Table S2 lists these probes with their splicing indices (SIs), the logratios of normalized exon values in depleted cells compared to the normalized exon values in control cells.
We used the MISO annotation to classify the 62 differential exon probes (Katz et al, 2010) . The distributions of differential RNA processing events upon depletion of either or both proteins are similar ( Figure 1A ). Alternative last exons are the most enriched, but skipped exons also represent a large number of events. We explored whether CELF1 and ELAVL1 repress or stimulate the use of each of the 62 exons covered by the probes. Figure 1B shows that all except one of the probes repressed by ELAVL1 are also repressed by CELF1, and that all but three of the probes stimulated by ELAVL1 are also stimulated by CELF1. This reveals that CELF1 and ELAVL1 essentially control splicing patterns in the same direction (p = 2 x 10 -10 , chi-square test).
We wondered how the double depletion of CELF1 and ELAVL1 effects splicing. To explore this, we plotted the sum of the splicing indices after each single depletion against the splicing indices after double depletion ( Figure 1C ). These values are highly correlated (R 2 = 0.93).
Importantly, the slope of the regression line is close to 1 (95% confidence interval 0.88-1.02).
Hence, the contribution of the two depletions to the splicing patterns in the doubly depleted cells equals the expectations from the additive effects of the individual depletions. This does not support any synergy nor redundancy between CELF1 and ELAVL1 in controlling RNA splicing patterns, and rather reveals additive controls.
Validation of splicing regulation mediated by CELF1 and ELAVL1
We chose a cassette exon of WNK1 to check the microarray results by RT-PCR. WNK1 has a broad expression pattern. It encodes a kinase with a key role in kidney and neural cell functioning (Rodan & Jenny, 2017) . It has a cassette exon that is regulated in a tissue-specific manner and which contributes to WNK1 protein level control by encoding a binding site for the E3 ubiquitin ligase NEDD4-2 (Vidal-Petiot et al, 2012; Roy et al, 2015) . Our microarray data reveal that both CELF1 and ELAVL1 repress the usage of this cassette exon (Table S2 ). By RT-PCR, WNK1 splicing pattern in non-transfected cells is very similar to that in cells transfected with either the control siRNA used in microarray experiments or an anti-luciferase siRNA (Figure 2A This shows that the control siRNA is essentially neutral when it comes to splicing patterns. We also observed that the inclusion of the cassette exon is stimulated in a similar manner when using the siRNAs against CELF1 together or separately (lanes 4-7), and the same is true for the siRNAs against ELAVL1 (lanes 8-10). Therefore, the changes observed in splicing patterns must not be due to siRNA off-target effects.
Next, we used PHACTR2 to investigate the specificity of the effect of the two depletions.
PHACTR2 mRNA encodes a phosphatase. It contains a cassette exon which is differentially included when CELF1 is depleted, but not with ELAVL1 depletion (Table S2) . As with WNK1, the control siRNA does not modify PHACTR2 splicing pattern, and the individual anti-CELF1 and anti-ELAVL1 siRNAs have the same effect as their combination ( Figure 2B ). However, as expected from the microarray data, when CELF1 (but not ELAVL1) is depleted, the long isoform containing the cassette exon is increased at the expense of the short one.
As an example of a more complex splicing pattern, we assessed CD44 splicing. CD44 is a hyaluronan-binding signal-transducing cell surface receptor. CD44 exons v2 to v10 are a series of cassette exons, and their inclusion or skipping produces many CD44 isoforms that have different effects on cancer progression (Prochazka et al, 2014) . Microarray hybridization showed that depletingCELF1 and/or ELAVL1 reduces the inclusion of exons v7 to v10, but this does not appear as significant for v7 and v9 after p-value adjustment ( Table S2 ). The flanking exons v6 and 15 are similarly included in all conditions. Of the 16 isoforms which can theoretically be produced by the combinatorial inclusion or skipping of four exons, we detected seven using RT-PCR with primers located in exons v6 and 15 ( Figure 2C ). As above, CD44's splicing pattern in non-transfected cells is very similar to that in cells transfected with either the control siRNA used in microarray experiments or an anti-luciferase siRNA (lanes 1, 2, 6). Importantly, in accordance with microarray data, all four alternative exons are repressed by the depletion of CELF1 or ELAVL1 (lanes 3-4), and are more strongly repressed by the simultaneous depletion of both proteins (lane 5). Together, these 7 145 150 155 160 RT-PCR data on skipped exons all corroborate the microarray results.
Finally, we carried out RT-PCR validations on splicing events annotated as "alternative last exons" ( Figure S2 ). MICAL3, SPTBN1, and PPP3CB encode a monooxygenase, a non-erythrocytic beta-II spectrin, and a calcium-dependent phosphatase, respectively. Each of these pre-mRNAs contains a terminal exon that can be also behave as an internal one, as it contains a 5' splice site.
Using this as a terminal exon results in a shorter C-terminal region in the encoded protein, with different subcellular localizations and molecular partners in the case of SPTBPN1 (Hayes et al, 2000) . As expected from the microarray results (Table S2) , the amounts of isoforms that result from using these as terminal exons are increased upon CELF1 depletion. They are also increased upon ELAVL1 depletion, but to a lesser extent ( Figure S2 ). Altogether, these RT-PCR results (Figures 2 and S2) are fully in accordance with the microarray data (Table S2 ).
CELF1 and ELAVL1 directly interact in the cell nucleus
Perhaps the joint regulation exerted by CELF1 and ELAVL1 on pre-mRNA processing is achieved by a macromolecular complex that contains these two proteins. The fact that they coimmunoprecipitate supports this interpretation (Le Tonquèze et al, 2010) . We used a fluorescence lifetime imaging-based Förster Fluorescence Resonance Energy Transfer (FRET) approach to test whether the CELF1-ELAVL1 interaction is direct, and to identify the subcellular compartment in which it takes place. The donor lifetime decreases when FRET occurs, which reveals a close proximity between the donor (EGFP) and the acceptor (mCherry) (Padilla-Parra & Tramier, 2012).
We expressed an EGFP-tagged version of CELF1 in HeLa cells. The nuclei of the cells expressing EGFP-CELF1 are green, with an EGFP fluorescence lifetime of about 2.5 ns (Figure 3 ). Those coexpressing an mCherry-tagged version of histone 2B (H2B) are yellow (Figure 3 , merge channel), indicating a co-localisation of EGFP-CELF1 and mCherry-H2B in the nuclei of transfected cells.
The unchanged lifetime of EGFP-CELF1 is consistent with a lack of interaction between CELF1 8 170 175 180 185 190 and H2B. In contrast, the lifetime of EGFP-CELF1 is reduced with a co-expressed mCherry-tagged version of CELF1, demonstrating the close proximity of EGFP and mCherry fluorophores, as expected due to CELF1's previously demonstrated ability to oligomerise (Cosson et al, 2006) . Importantly, mCherry-ELAVL1 also reduces the fluorescence lifetime of EGFP-CELF1 to a similar extent ( Figure 3 ). Quantifying fluorescence lifetime in several nuclei demonstrated a highly significant decrease in the presence of mCherry-ELAVL1 (p < 2.2 x 10 -16 , Wilcoxon test) (Figure 3 , lower panel). Swapping the two fluorophores produced the same results ( Figure S3 ). We conclude therefore that CELF1 and ELAVL1 directly interact within a complex in the nucleus.
CELF1 and ELAVL1 levels are correlated with human cancer prognosis
We show above that CELF1 and ELAVL1 control mRNA splicing together. Because HeLa cells come from cervical carcinoma, we used the TCGA (The Cancer Genome Atlas) uterine carcinosarcoma panel to test the relevance of the additive functions of these proteins in human pathology. Statistically, the survival rates of patients with either low and high ELAVL1 mRNA levels are similar ( Figure 4A ), and the prognosis for patients with high CELF1 levels is hardly better than that for those with low levels (p = 0.025, log-rank test, Figure 4B ). Importantly, however, patients with low levels of both CELF1 and ELAVL1 have a worse survival rate (p = 9.7 x 10 -4 ) than patients with a high level of CELF1 and/or ELAVL1 ( Figure 4C ). These data show that a more accurate prognosis can be given for uterine carcinosarcoma patients when both CELF1 and ELAVL1 mRNA levels are considered together rather than separately.
To expand these findings, we investigated the other TCGA cohorts. From them, we chose the cohorts where the effects of either low or high levels of CELF1 and ELAVL1 on patient prognosis are in the same direction, and removed those for which survival rates cannot be predicted (p > 0.1) by neither CELF1 nor ELAVL1 levels. We also removed those where the CELF1 or ELAVL1 levels alone are enough to separate the patients into two groups with different survival 9 195 200 205 210 rates (p < 0.01 for at least one gene). For the ten resulting cohorts, we drew Kaplan-Meier curves for the levels of CELF1, ELAVL1, and both, and we compared the corresponding log-rank p-values ( Figure 4D ). For eight of the ten cohorts, we obtained lower p-values when looking at the levels of both CELF1 and ELAVL1. The corresponding Kaplan-Meier curves are shown in Figure S4 . These data indicate that the combined mRNA levels of CELF1 and ELAVL1 may be a valuable biomarker in a variety of human cancers.
CD44 has a demonstrated role in cancer progression (Prochazka et al, 2014) , and it is controlled by CELF1 and ELAVL1 at the splicing level. We therefore retrieved the data for the usage of CD44 variable exons v6 to v10 (see Figure 2C ) from TCGA SpliceSeq (Ryan et al, 2016) .
We investigated the eight above cohorts to see if there is a correlation between inclusion of these exons and the mRNA levels of CELF1 and ELAVL1. Figure 4E shows that in breast invasive cancers (BRCA) and lung squamous cell carcinoma (LUSC), tumours having low levels of both CELF1 and ELAVL1 mRNA also have a significantly lower percentage of CD44 isoforms containing exons v6 to v10 (CD44v or CD44 variant). This is consistent with our results showing that CELF1 and ELAVL1 stimulate the inclusion of at least exons v7 to v10 in HeLa cells ( Figure   2C ). In breast invasive carcinoma, the survival rates are worse for patients with high CELF1 and ELAVL1 mRNA levels, as well as for those having a high percentage of CD44v ( Figure 4F ).
Conversely, in lung squamous cell carcinoma, the survival rate is not worse but better when those same parameters are present ( Figure 4G ). Hence, although in both types of cancer the proteins CELF1 and ELAVL1 seem to promote CD44v by stimulating exon v7-v10 inclusion, the effects of this on patient prognosis are apparently completely different.
Conclusion
Previous studies demonstrated an antagonism between ELAVL1 and CELF1 in translational control: in intestinal cells ELAVL1 stimulates the translation of CDH1 (E-cadherin), OCLN 10 220 225 230 235 240 (Occludin), and MYC, whereas CELF1 represses them (Yu et al, 2016; Liu et al, 2015; Yu et al, 2013) . In contrast, here we see that these RNA-binding proteins actually cooperate, dictating mRNA splicing patterns. Our FRET experiments show that CELF1 and ELAVL1 are in direct contact in the nucleus, which supports the idea that they work together by belonging to the same macromolecular complex. This putative large complex may also include previously identified molecular partners of CELF1 such as HNRNPH1 and H2 (Paul et al, 2006) , and/or partners of ELAVL1, such as HNRNPK (Hegele et al, 2012) , HNRNPL (Matsui et al, 2008) and IGF2BP1 (Weidensdorfer et al, 2009 ).
Our findings considerably deepen the link between certain cancers and CELF1 and ELAVL1. It was already known that CELF1 protein levels are negatively correlated with patient survival in glioma and non-small-cell lung cancers (Xia et al, 2015; Jiao et al, 2013) . This is also the case for ELAVL1 in ovarian high-grade serous carcinoma, colorectal cancer, and hepatocellular carcinoma (Davidson et al, 2016; Yoo et al, 2009; Zhu et al, 2015) . We examined eight cohorts from a wide range of human tumours, and demonstrated that better prognostic values result from considering the expressions of both CELF1 and ELAVL1 than if these values are examined on their own. The cooperation between CELF1 and ELAVL1 in RNA splicing control provides a likely explanation for this.
One surprising observation is that high levels of CELF1 and ELAVL1 have opposite effects on patient survival in the presence of different types of cancer. BLCA, LUSC, UCS, or UVM patients who have high levels of CELF1 and ELAVL1 have better survival chances, but the opposite is true for patients with ACC, BRCA, SARC, or UCEC. An obvious explanation for this is that the transcriptomes of these tumours differ, as do the RNAs controlled by these two proteins. However, our CD44 findings suggest an additional hypothesis. In breast cancer, a switch occurs during the epithelial-mesenchymal transition (EMT) from a CD44v isoform (containing exons v8-v10) to the standard CD44s isoform (devoid of the alternative cassette exons). This isoform switch is essential 11 245 250 255 260 for EMT (Brown et al, 2011) . CD44 isoforms correlate with different cancer cell states, with CD44s associated with cell stemness, while CD44v is associated with cell proliferation (Zhang et al, 2019) .
Cell stemness and proliferation can both negatively impact patient survival, but perhaps in different ways for different tumour types. This would explain why CD44v percentages have contrary consequences for patient prognosis in breast and lung cancers (Figure 4) . Globally, CELF1 and ELAVL1 may exert identical control of the same targets in different cancer types, but with disparate patient outcomes.
MATERIALS AND METHODS
Sequences and constructs
The sequences of the siRNAs and primers are given in the Supplemental material section.
To construct plasmids EGFP-ELAVL1, mCherry-ELAVL1, EGFP-CELF1, and mCherry-CELF1, the cDNAs encoding ELAVL1 or CELF1 were introduced into the pENTR directional TOPO vector (Invitrogen), then inserted via Gateway recombination (Invitrogen) into the final 223 pCS EGFP DEST or 362 pCS Cherry DEST (Addgene) vectors.
Cell manipulations and RNAi
We cultured HeLa Kyoto cells at 37 °C, 5% CO 2 in DMEM (Gibco) with 10% fetal calf serum (PAA), 100 U/ml penicillin and 100 μg/ml st g/ml streptomycin (Gibco). For RNAi, we used jetPRIME (Polyplus) to transfect the cells with the siRNAs indicated in the supplemental Material section. All experiments resulted in the same total concentration of 10 nM siRNAs. This was achieved by mixing the following siRNAs: 5 nM control plus 5 nM anti-ELAVL-1 siRNAs; 5 nM control plus 5 nM anti-CELF1 siRNAs; 5 nM anti-ELAVL-1 plus 5 nM anti-CELF1 siRNAs; 10 nM control siRNAs; and 10 nM anti-luciferase siRNAs. After 48 h, we recovered the cells for 12 270 275 280 285 290 sampling in 500 μg/ml st l of PBS by scraping after three washes with cold PBS then centrifuging for 5 min at 3000 rpm at 4 °C.
FRET-FLIM
HeLa Kyoto cells were seeded at 20% confluence in observation chambers on 4-well glass slides (Dustcher). These were then transfected (jetPRIME) with 15 ng of the expression vectors of EGFP-labelled proteins in the presence or absence of 150 ng of vector that expresses mCherrylabelled proteins. After 24 h, the cells were washed with PBS and observed at 37 °C.
FRET experiments were conducted with a fastFLIM system using a plan APO 63x/1.4NA oil immersion objective (Leica). For EGFP donor excitation, a narrow 480/23 nm spectral band was selected from a Fianium white-light laser and sent to the CSUX1 microscope (Yokogawa) through a dichroic mirror (Di01-T405/488/568/647, Semrock) inside the spinning head. EGFP emissions were filtered on the spinning filter wheel (525/50 nm), then acquired with a time-gated intensified CCD camera (Picostar, LaVision or CoolSNAP HQ2, Roper). Five temporal gates of 2.25 ns were acquired sequentially by step-by-step adjustments of the laser signal delay to trigger the gated intensifier. Depending on the brightness of the sample, the CCD camera exposure time was between 500 ms and 2 s. The FLIM calculation to determine the mean fluorescence lifetime in a pixel-bypixel basis was done online using flimager (Leray et al, 2013) . For every nucleus region where lifetimes were measured, we checked for the absence of photo-bleaching and for the presence of both fluorophores for doubly transfected cells. Three independent series of transfection were carried out, with ten cells were analysed for each series, resulting in a total of 30 nuclei analysed per condition.
Protein analysis
Cell pellets (equivalent to a 10-cm Petri dish with 80-90% confluence) were lysed with 13 295 300 305 310 RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, 0.1% P8340 Sigma protease inhibitor). After incubation for 10 min at room temperature, the samples were sonicated with a microprobe and centrifuged at 10,000 rpm for 5 min at 4 °C.
Proteins were separated by electrophoresis and electrotransferred onto Hybond C Plus membranes (GE-Healthcare) per standard western blot procedures with anti-CELF1 (3B1 sc-20003, SantaCruz), anti-PCNA (p8825, Sigma-Aldrich), or anti ELAV1 (sc-5261, SantaCruz) primary antibodies, or with anti-mouse secondary antibodies. Imaging was done with a LI-COR Odyssey imager.
RNA analysis
We treated the cells for 48 h with siRNAs. Three independent depletions were carried out for each condition. Total RNAs were extracted with TRIzol (Invitrogen) or a NucleoSpin RNA extraction kit (Macherey-Nagel), treated with Turbo DNase (Ambion), then sent to the Plateforme Génomique de Nantes for hybridization on SurePrint G3 human exon microarrays (Agilent). Raw signals were LOWESS-normalised before analysis. Alternatively, they were used as matrices to synthesize cDNA using random primers and SuperScript II reverse transcriptase (Invitrogen). PCR was done on cDNAs using unlabelled, Cy3-labelled, or 32 P-labelled primers. Unlabelled RT-PCR (PPP3CB, MICAL3) results were analysed by SYBR staining after electrophoresis. The 32 P-labelled RT-PCR (CD44) results were analysed by autoradiography. The Cy3-labelled RT-PCR (WNK1, SPTBN1, PHACTR2) results were treated as follows. DNA strands were prepared with a genespecific forward primer having an M13 tail (CGCCAGGGTTTTCCCAGTCACGAC) for five cycles. These DNA strands were then used as PCR matrices with a Cy3-labelled M13 primer oligonucleotide and a gene-specific reverse primer. After electrophoresis, amplimere ratios were measured from the fluorescence intensities on a Typhoon imager (Amersham). In all the cases, the number of PCR cycles was determined empirically for each primer pair in order to remain within the exponential phase of amplification. 14 320 325 330 335
Data analysis
The raw microarray data are available in GEO as data set GSE118981. For TCGA, we retrieved the data from Firebrowse (http://firebrowse.org/) and TCGA SpliceSeq (Ryan et al, 2016) .
We analysed all data using in-house R scripts, and these are available in the Supplemental material section. v10) that have negative splicing indices after depletion of CELF1 or ELAVL1. C+E, mixture of 3 siRNAs against CELF1 and 2 siRNAs against ELAVL1, as used in the microarray experiments. RT-PCR were done with primers located in exons labelled v6 and 15. Lower panel, we calculated the cumulative percentages of all isoforms containing the exons of interest: for exon v7, isoforms 1, 3, and 6; for v8 and v9, isoforms 1 to 4; and for exon v10, isoforms 1, 2, and 5. 
